Meeting FMD challenges
Together, the partners aim to offer the pharma industry a complete range of versatile solutions to FMD challenges in tracing, tracking and tamper-evident applications. The FMD will compel the pharma industry by Feb 9th 2019 to offer a tamper evident solution on all packaged and boxed products.
Avery Dennison has recently developed a dedicated pharma adhesive, S799P, that generates fiber tear when opening the varnished folding boxes typically used for prescription drugs, making any tampering highly visible.
Weber has already qualified S799P combined with a thin PP film face (polypropylene) on label conversion, adding specific die cuts to make the label more fragile, and on label application, where Weber has developed a dedicated tamper evident labeler that supports high speed application. The compact tamper evident labeller reliably seals up to 500 folding cartons per minute from two sides.
“Together with Weber, we can control label materials, conversion and application across our entire manufacturing and logistics chain,” commented Gabriela Gregor, Product Manager Pharmaceuticals Avery Dennison Materials Group Europe.
“Our collaboration allows us to offer pharmaceutical clients, including packaging and regulatory communities, quality and operations directors a complete one-stop shop solution,” said Ms. Gregor.
Frederic Bussy, Managing Director of Weber Marking Systems, France, added: “Pharma manufacturers have to invest in solutions to comply with FMD. They are looking for a versatile solution that can be retrofitted to existing packaging lines. A self-adhesive tamper evident label offers flexibility and efficiency in manufacturing .”
“Contrary to comparable solutions in the industry, the tamper evident labeller has the great advantage that it has a very reduced footprint and can be operated from one side. As a result, it can be flexibly integrated into cramped production environments or large plants.
Furthermore, transparent labelling allows use with existing artwork and is more patient friendly,” Mr. Bussy explained.
Furthermore, Frederic Bussy advises pharmaceutical companies on the issue of aggregation. This means that the individual personalized drug packages must be packed in carton, bundle and pallet and marked individually on these higher packaging levels. The aggregation is not required under the EU regulation but it brings advantages as it facilitates logistics processes but also, for example, recalls.